Loading…

Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report

Glioblastoma multiforme is a highy aggressive tumor that recurs despite resection, focal beam radiation, and temozolamide chemotherapy. ERC-1671 is an experimental treatment strategy that uses the patient's own immune system to attack the tumor cells. The authors report preliminary data on the...

Full description

Saved in:
Bibliographic Details
Published in:Permanente journal 2015, Vol.19 (2), p.41-46
Main Authors: Bota, Daniela A, Alexandru-Abrams, Daniela, Pretto, Chrystel, Hofman, Florence M, Chen, Thomas C, Fu, Beverly, Carrillo, Jose A, Schijns, Virgil Ejc, Stathopoulos, Apostolos
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma multiforme is a highy aggressive tumor that recurs despite resection, focal beam radiation, and temozolamide chemotherapy. ERC-1671 is an experimental treatment strategy that uses the patient's own immune system to attack the tumor cells. The authors report preliminary data on the first human administration of ERC-1671 vaccination under a single-patient, compassionate-use protocol. The patient survived for ten months after the vaccine administration without any other adjuvant therapy and died of complications related to his previous chemotherapies.
ISSN:1552-5767
1552-5775
DOI:10.7812/TPP/14-042